LOS ANGELES, July 24, 2014 /PRNewswire/ -- Bruin Biometrics (BBI), a pioneer in biometric-sensor based medical devices, announced today that after two weeks of clinical briefings to over 200 pressure ulcer experts throughout the European Union, it gained substantial concurrence on both the clinical validity of SEM (sub-epidermal moisture) and the clinical utility of BBI's SEM Scanner.
"From our post-briefing surveys, over 90 percent of the respondents drawn from the European Wound Management Association (EWMA) and European Pressure Ulcer Advisory Panel (EPUAP) agree that SEM is a meaningful biomarker for early indication – up to 10 days before damage is visible on the skin – of pressure-induced tissue damage, acknowledging years of research led by Professor Barbara Bates-Jensen of UCLA," said Mark Bruns, VP of Sales for Bruin Biometrics. "Slightly more than 40 percent of those surveyed provided responses. Of those, a substantial majority further agreed that our SEM Scanner can be used to assess pressure-induced tissue damage. We're honored to have the support of the international community of pressure ulcer experts as we take the next steps to market this innovative device to wound management clinicians worldwide."
About Bruin Biometrics
Bruin Biometrics LLC, a pioneer in biometric-sensor based medical devices is committed to earlier and significantly better diagnosis of select chronic clinical conditions that enable clinicians to provide proactive, targeted interventions that are more cost effective.
SEM scanner is CE Mark approved and is currently in full commercial launch in the EU. SEM Scanner is awaiting FDA clearance and is not currently for sale in the United States. To learn more about BBI and the SEM Scanner, please visit www.bruinbiometrics.com.
|SOURCE Bruin Biometrics, LLC|
Copyright©2014 PR Newswire.
All rights reserved